Nesta página
BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 5, 2026
$8,17
· % da faixa de 52 semanas
· acima do mínimo
· para alta
$6,00mínima 52 sem
$11,22máxima 52 sem
Capitalização de Mercado (MRQ)
$2.09B
P/E (TTM)
-5.5
EPS (TTM)
$-1.49
Receita (TTM)
$941M
seus distintivos
Intervalo 52 Semanas
$6–$11
Classificação do Analista
BUY
Preço-Alvo
$21
P/E
-5.5
ROE
87.8%
Margem de Lucro Líquido
-40.9%
Sua barra de distintivos está vazia — fixe uma métrica em qualquer lugar desta página.
BCRX Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$8.17
Capitalização de Mercado (MRQ)
$2.09B
P/E (TTM)
-5.5
EPS (TTM)
$-1.49
Receita (TTM)
$941M
ROE (TTM)
87.8%
Dívida/Capital (MRQ)
-0.9
Intervalo 52 Semanas
$6–$11
BCRX Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
intervalo
barras
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
Sobre BioCryst Pharmaceuticals, Inc. - Common Stock Visão geral da empresa da Wikipedia
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
setorHealthcare
indústriaBiotechnology
funcionários435
paísUS
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita$875M2016-12-31 → 2025-12-31
EPS$1.212020-12-31 → 2025-12-31
Fluxo de caixa livre$345M2016-12-31 → 2025-12-31
Margem líquida-40.9%2016-12-31 → 2025-12-31
Avaliação e Proporções
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | BCRX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E (TTM) | -5.5média 5A ≈-7.6 | ≈-7.6 | · | · | |
| P/S (TTM) | 2.2média 5A ≈6.7 | ≈6.7 | 29.2 | Subvalorizado | |
| P/B (MRQ) | -4.6média 5A ≈-10.2 | ≈-10.2 | · | · | |
| EV / EBITDA | 5.3média 5A ≈-281.5 | ≈-281.5 | · | · | |
| Preço / FCF (TTM) | 5.6média 5A ≈-13.6 | ≈-13.6 | · | · | |
| Preço / Fluxo de Caixa (TTM) | 5.5média 5A ≈-13.9 | ≈-13.9 | · | · | |
| EV / Receita (TTM) | 2.3média 5A ≈6.3 | ≈6.3 | · | · | |
| EV / FCF (TTM) | 5.7média 5A ≈-14.4 | ≈-14.4 | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | BCRX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Margem Operacional (TTM) | -33.3%média 5A ≈-32.2% | ≈-32.2% | -1041.7% | Primeira linha | |
| EBITDA Margin (Margem EBITDA) | 39.1%média 5A ≈-31.8% | ≈-31.8% | -1041.7% | Primeira linha | |
| Margem de Impostos Pré-Tributação (TTM) | -40.5%média 5A ≈-52.6% | ≈-52.6% | -493.4% | Primeira linha | |
| Margem de Lucro Líquido (TTM) | -40.9%média 5A ≈-53.3% | ≈-53.3% | -990.1% | Primeira linha | |
| ROA (TTM) | -75.8%média 5A ≈-18.2% | ≈-18.2% | -40.3% | Primeira linha | |
| ROE (TTM) | 87.8%média 5A ≈42.1% | ≈42.1% | -55.6% | Fraco | |
| ROIC | -282.4%média 5A ≈-118.5% | ≈-118.5% | -55.2% | Fraco |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | BCRX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido (MRQ) | -0.9média 5A ≈-0.7 | ≈-0.7 | 0.0 | Baixa dívida | |
| Índice de liquidez corrente (MRQ) | 2.3média 5A ≈3.7 | ≈3.7 | 6.7 | Baixa liquidez | |
| Índice de Liquidez Seca (MRQ) | 2.2média 5A ≈2.5 | ≈2.5 | 4.5 | Baixa liquidez | |
| Dívida de Longo Prazo / Patrimônio Líquido (MRQ) | -0.9média 5A ≈-0.7 | ≈-0.7 | 0.2 | Baixa dívida |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | BCRX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | 94.1%média 5A ≈201.4% | ≈201.4% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | 47.8%média 5A ≈85.0% | ≈85.0% | · | · | |
| Revenue CAGR 5Y (CAGR Receita 5A) | 117.9% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | BCRX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 1.7média 5A ≈0.8 | ≈0.8 | 0.1 | Primeira linha | |
| Inventory Turnover (Giro de Estoque) | 2.8média 5A ≈0.9 | ≈0.9 | · | · | |
| Receivables Turnover (Giro de Contas a Receber) | 9.4média 5A ≈7.4 | ≈7.4 | · | · | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$2.0M | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
23.2%
Próximo relatório
Nov 02, 2026
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 3, 2026 | $0.30 | $0.12 | 148.1% |
| 31 de Março de 2026 | $-0.09 | $0.05 | -281.8% | |
| 31 de Dezembro de 2025 | $0.01 | $0.04 | -74.1% | |
| 30 de Setembro de 2025 | $0.06 | $0.04 | 67.1% | |
| 30 de Junho de 2025 | $0.04 | $0.01 | 179.7% | |
| 31 de Março de 2025 | $0.00 | $-0.07 | 100.0% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.56 | $-2.28 | $-2.21 | $-1.57 | $-0.58 | $-0.11 | $0.25 | $0.45 | · | $0.02 | $0.65 | $1.05 | |
| Revenue / Share | $4.00 | $2.18 | $1.72 | $1.46 | $0.88 | $0.11 | $0.42 | $0.20 | · | $0.36 | $0.66 | · | |
| Cash Flow / Share | $1.59 | $-0.25 | $-0.49 | $-0.87 | $-0.79 | $-0.82 | $-0.77 | $-0.90 | · | $-0.73 | $-0.18 | · | |
| Cash / Share | $0.42 | $0.50 | $0.54 | $1.62 | $2.74 | $1.54 | $0.74 | $0.24 | · | $0.30 | $0.39 | $0.76 | |
| EPS (TTM) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-0.61 | $-0.61 | $-0.61 | $-0.61 | $-0.60 | · |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | · | 210,176,000 | 209,519,000 | 208,882,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | · | 219,885,000 | 219,886,000 | 215,261,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.78 | $-2.18 | · | $-1.84 | $-2.01 | $-2.16 | · | $-2.26 | $-2.30 | $-2.31 | · | $-2.17 | $-2.05 | $-1.74 | · | $-1.30 | |
| Revenue / Share | $0.82 | $0.65 | · | $0.72 | $0.74 | $0.68 | · | $0.57 | $0.53 | $0.45 | · | $0.46 | $0.44 | $0.36 | · | $0.41 | |
| Cash Flow / Share | · | $-0.26 | · | · | · | $-0.13 | · | · | · | $-0.26 | · | · | · | $-0.25 | · | · | |
| Cash / Share | $0.61 | $0.68 | · | $0.40 | $0.42 | $0.50 | · | $0.47 | $0.38 | $0.41 | · | $0.80 | $0.77 | $0.82 | · | $1.32 | |
| EPS (TTM) | $-1.49 | $-1.77 | · | $-0.05 | $-0.18 | $-0.26 | · | $-0.61 | $-0.73 | $-1.07 | · | $-1.25 | $-1.29 | $-1.21 | · | $-1.05 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $941M | $886M | · | $600M | $558M | $503M | · | $413M | $382M | $355M | · | $318M | $307M | $290M | · | $238M | |
| Net Income TTM | $-385M | $-458M | · | $-9M | $-36M | $-53M | · | $-124M | $-146M | $-209M | · | $-236M | $-243M | $-226M | · | $-193M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -6.7 | -5.4 | · | -151.8 | -49.8 | -28.8 | · | -12.5 | -8.5 | -4.7 | · | -5.7 | -5.5 | -6.9 | · | -12.0 | |
| P/S | 2.7 | 2.7 | · | 2.7 | 3.4 | 3.1 | · | 3.8 | 3.3 | 2.9 | · | 4.2 | 4.4 | 5.4 | · | 9.9 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| EV / Revenue | 2.8 | 2.9 | · | 2.6 | 3.3 | 3.2 | · | 4.3 | 4.0 | 3.6 | · | 4.7 | 4.8 | 5.7 | · | 9.8 | |
| Earnings Yield | -14.9% | -18.6% | · | -0.66% | -2.0% | -3.5% | · | -8.0% | -11.8% | -21.1% | · | -17.7% | -18.3% | -14.5% | · | -8.3% |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Receita | $875M | $451M | $331M | $271M | $157M |
| Margem Operacional % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| Lucro líquido | $264M | $-89M | $-227M | $-247M | $-184M |
| EPS Diluído | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| Índice de liquidez corrente | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| Índice de Liquidez Seca | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $345M | $-53M | $-97M | $-163M | $-145M |
Investidores institucionais (13F) 345 declarantes · $2.8B total · Em 30 de Setembro de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Detentores
345
Valor detido
$2.8B
Novas posições
55
Posições encerradas
34
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 55 (-22 vs trimestre anterior) | 34 (-5 vs trimestre anterior) | 137 (+20 vs trimestre anterior) | 87 (+8 vs trimestre anterior) | +4.1M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $238.930.360 | 23.893.036 | 8,46% | Ações |
| VANGUARD GROUP INC | $173.732.325 | 22.273.375 | 6,15% | Ações |
| RA CAPITAL MANAGEMENT, L.P. | $158.271.860 | 15.827.186 | 5,61% | Ações |
| STATE STREET CORP | $151.910.980 | 15.191.098 | 5,38% | Ações |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150.964.030 | 15.096.403 | 5,35% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $113.642.360 | 11.364.236 | 4,03% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111.391.580 | 11.139.158 | 3,95% | Ações |
| TCG Crossover Management, LLC | $110.209.680 | 11.020.968 | 3,90% | Ações |
| PERCEPTIVE ADVISORS LLC | $103.088.880 | 10.308.888 | 3,65% | Ações |
| JANUS HENDERSON GROUP PLC | $84.853.520 | 8.908.506 | 3,01% | Ações |
| Vestal Point Capital, LP | $83.000.000 | 8.300.000 | 2,94% | Ações |
| TWO SIGMA INVESTMENTS, LP | $67.753.490 | 6.775.349 | 2,40% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $62.493.232 | 6.248.046 | 2,21% | Ações |
| Aberdeen Group plc | $53.108.710 | 5.310.871 | 1,88% | Ações |
| UBS Group AG | $50.782.800 | 5.078.280 | 1,80% | Ações |
| BANK OF AMERICA CORP /DE/ | $48.012.840 | 4.801.284 | 1,70% | Ações |
| GOLDMAN SACHS GROUP INC | $44.818.738 | 4.481.874 | 1,59% | Ações |
| Frazier Life Sciences Management, L.P. | $40.092.400 | 4.009.240 | 1,42% | Ações |
| Nuveen, LLC | $40.072.370 | 4.007.237 | 1,42% | Ações |
| MILLENNIUM MANAGEMENT LLC | $33.947.290 | 3.394.729 | 1,20% | Ações |
| TWO SIGMA ADVISERS, LP | $31.895.074 | 4.089.112 | 1,13% | Ações |
| RP Management, LLC | $28.846.155 | 3.846.154 | 1,02% | Ações |
| JANE STREET GROUP, LLC | $27.626.830 | 2.762.683 | 0,98% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $27.187.810 | 2.718.781 | 0,96% | Ações |
| Fisher Asset Management, LLC | $26.040.270 | 2.604.027 | 0,92% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $25.302.900 | 2.530.290 | 0,90% | Ações |
| Kynam Capital Management, LP | $25.226.600 | 2.522.660 | 0,89% | Ações |
| Candriam S.C.A. | $25.125.293 | 2.514.949 | 0,89% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23.532.910 | 2.353.291 | 0,83% | Ações |
| RICE HALL JAMES & ASSOCIATES, LLC | $23.320.430 | 2.332.043 | 0,83% | Ações |
| NORTHERN TRUST CORP | $22.557.310 | 2.255.731 | 0,80% | Ações |
| AQR CAPITAL MANAGEMENT LLC | $22.143.020 | 2.214.302 | 0,78% | Ações |
| MORGAN STANLEY | $19.996.852 | 1.999.684 | 0,71% | Ações |
| Nantahala Capital Management, LLC | $19.011.600 | 1.901.160 | 0,67% | Ações |
| Eversept Partners, LP | $18.656.530 | 1.865.653 | 0,66% | Ações |
| ORBIMED ADVISORS LLC | $18.520.000 | 1.852.000 | 0,66% | Ações |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18.449.120 | 1.844.912 | 0,65% | Ações |
| STIFEL FINANCIAL CORP | $18.262.340 | 1.826.234 | 0,65% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $17.595.730 | 1.759.573 | 0,62% | Ações |
| CITADEL ADVISORS LLC | $17.591.600 | 1.759.160 | 0,62% | Ações |
| JUPITER ASSET MANAGEMENT LTD | $16.428.740 | 1.642.874 | 0,58% | Ações |
| IMC-Chicago, LLC | $16.343.360 | 1.634.336 | 0,58% | Ações |
| Parkman Healthcare Partners LLC | $16.242.790 | 1.624.279 | 0,58% | Ações |
| Legal & General Group Plc | $14.555.141 | 1.455.514 | 0,52% | Ações |
| OP Asset Management Ltd | $13.409.900 | 1.340.990 | 0,48% | Ações |
| Invesco Ltd. | $12.337.830 | 1.233.783 | 0,44% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.956.510 | 1.195.651 | 0,42% | Ações |
| Pictet Asset Management Holding SA | $11.951.392 | 1.249.771 | 0,42% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $11.740.520 | 1.174.052 | 0,42% | Ações |
| FIRST TRUST ADVISORS LP | $11.204.690 | 1.120.469 | 0,40% | Ações |
Ativistas e proprietários de 5%+ 15 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 declarações | 31 de Julho de 2018 | · | Declaração inicial | · | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 2 de Abril de 2018 | · | Declaração inicial | Investimento passivo | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 declarações | 16 de Agosto de 2016 | · | Declaração inicial | · | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 declarações | 23 de Outubro de 2012 | · | Declaração inicial | M&A / venda | SEC |
| Julian C. Baker, Felix J. Baker ×4 declarações | 13 de Outubro de 2011 | · | Declaração inicial | · | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 declarações | 20 de Agosto de 2007 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 7 de Dezembro de 2005 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 7 de Dezembro de 2005 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 7 de Dezembro de 2005 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada | 13 de Outubro de 2005 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 26 de Fevereiro de 2004 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 25 de Fevereiro de 2004 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 24 de Fevereiro de 2004 | · | Declaração inicial | · | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 declarações | 31 de Outubro de 2003 | · | Declaração inicial | · | SEC |
| William W. Featheringill | 14 de Fevereiro de 2002 | · | Declaração inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 51 insiders · 21 diretores · 30 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 17 de Dezembro de 2025 A | 268.700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 19 de Dezembro de 2024 A | 377.867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 21 de Fevereiro de 2020 A | 125.176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 16 de Março de 2011 M | 57.102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 22 de Dezembro de 2025 M | 952.583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 14 de Março de 2008 A | 65.730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 13 de Maio de 2026 M | 400.703 | 0 | 7 | $-3.461.969 |
| Sandeep Menon | Chief R&D Officer | 6 de Abril de 2026 A | 205.150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 31 de Março de 2025 F | 377.318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 19 de Dezembro de 2022 A | 16.653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 14 de Novembro de 2022 M | 298.541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 10 de Março de 2022 M | 37.954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 15 de Dezembro de 2020 A | 45.000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 28 de Janeiro de 2019 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 15 de Março de 2012 F | 24.124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 7 de Fevereiro de 2011 A | 9.766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 12 de Março de 2010 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 31 de Julho de 2008 P | 3.048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 31 de Julho de 2007 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 31 de Julho de 2007 P | 3.659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 16 de Maio de 2007 A | 1.928 | 0 | 0 | $0 |
| Amy E Mckee | Conselheiro | 31 de Agosto de 2026 A | 47.821 | 0 | 1 | $-100.285 |
| Jill C. Milne | Conselheiro | 31 de Agosto de 2026 A | 33.226 | 0 | 0 | $0 |
| Steven Frank | Conselheiro | 31 de Agosto de 2026 A | 36.747 | 0 | 0 | $0 |
| Jon P Stonehouse | Conselheiro | 31 de Agosto de 2026 A | 1.340.419 | 0 | 0 | $0 |
| Vincent Milano | Conselheiro | 31 de Agosto de 2026 A | 109.642 | 0 | 0 | $0 |
| Theresa Heggie | Conselheiro | 11 de Junho de 2026 A | 80.646 | 0 | 1 | $-504.823 |
| Machelle Sanders | Conselheiro | 11 de Junho de 2026 A | 45.936 | 0 | 1 | $-68.544 |
| Steven K Galson | Conselheiro | 11 de Junho de 2026 A | 27.794 | 0 | 0 | $0 |
| Alan G Levin | Conselheiro | 11 de Junho de 2026 A | 79.565 | 0 | 0 | $0 |
| Nancy J Hutson | Conselheiro | 12 de Junho de 2025 A | 99.138 | 0 | 0 | $0 |
| George B Abercrombie | Conselheiro | 12 de Junho de 2024 A | 36.431 | 0 | 0 | $0 |
| Steve Aselage | Conselheiro | 12 de Junho de 2024 A | 70.159 | 0 | 0 | $0 |
| Kenneth B Lee JR | Conselheiro | 13 de Junho de 2023 A | 68.863 | 0 | 0 | $0 |
| Robert Alexander Ingram | Conselheiro | 28 de Fevereiro de 2023 A | 100.198 | 0 | 0 | $0 |
| Stanley C Erck | Conselheiro | 28 de Novembro de 2018 M | 48.333 | 0 | 0 | $0 |
| Fred Cohen | Conselheiro | 20 de Junho de 2018 A | 119.410 | 0 | 0 | $0 |
| Sanj K Patel | Conselheiro | 24 de Maio de 2017 A | · | 0 | 0 | $0 |
| Charles A Sanders | Conselheiro | 29 de Fevereiro de 2016 A | 12.971 | 0 | 0 | $0 |
| Peder Jensen | Conselheiro | 2 de Maio de 2014 A | 60.000 | 0 | 0 | $0 |
| John L Higgins | Conselheiro | 23 de Maio de 2012 A | · | 0 | 0 | $0 |
| HOROVITZ ZOLA P | Conselheiro | 23 de Maio de 2012 A | 3.000 | 0 | 0 | $0 |
| Stephen R Biggar | Conselheiro | 12 de Maio de 2011 A | · | 0 | 0 | $0 |
| Beth C Seidenberg | Conselheiro | 13 de Maio de 2010 A | 3.000 | 0 | 0 | $0 |
| William W Featheringill | Conselheiro | 13 de Maio de 2010 A | 231.538 | 0 | 0 | $0 |
| William M Spencer III | Conselheiro | 16 de Maio de 2007 A | 186.761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | Conselheiro | 16 de Maio de 2007 A | 451.900 | 0 | 0 | $0 |
| Charles E Bugg | Conselheiro | 18 de Março de 2007 A | 62.439 | 0 | 0 | $0 |
| GORDON CARL L | Conselheiro | 17 de Maio de 2006 A | 1.100.000 | 0 | 0 | $0 |
| John A Montgomery | Conselheiro | 4 de Novembro de 2003 M | 46.785 | 0 | 0 | $0 |
| Randolph C Steer | · | 21 de Maio de 2008 A | · | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 41 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,35% | 1.193.733 SH | 1 de Outubro de 2026 | Diário |
| BBP · ETFis Series Trust I | 1,42% | 155.993 NS | 31 de Julho de 2026 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 0,99% | 510 NS | 31 de Julho de 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,92% | 1.078.429 NS | 31 de Julho de 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,62% | 248.560 NS | 31 de Julho de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,59% | 324.702 NS | 31 de Julho de 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,36% | 516.595 NS | 31 de Julho de 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,23% | 73.039 SH | 1 de Outubro de 2026 | Diário |
| PWS · Pacer Funds Trust | 0,17% | 4.436 NS | 31 de Julho de 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,14% | 249.665 SH | 19 de Agosto de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,14% | 18.119 SH | 1 de Outubro de 2026 | Diário |
| ESSC · Strategy Shares | 0,14% | 5.593 NS | 31 de Julho de 2026 | N-PORT |
| IBB · iShares Trust | 0,13% | 1.651.139 SH | 11 de Setembro de 2026 | Diário |
| IWO · iShares Trust | 0,13% | 2.178.966 SH | 11 de Setembro de 2026 | Diário |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,11% | 174.467 NS | 31 de Julho de 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 64.429 NS | 31 de Julho de 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,07% | 46.799 NS | 31 de Julho de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 1.339.774 SH | 19 de Agosto de 2026 | Diário |
| RSSL · Global X Funds | 0,07% | 111.471 NS | 31 de Julho de 2026 | N-PORT |
| ISCG · iShares Trust | 0,06% | 75.067 SH | 11 de Setembro de 2026 | Diário |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,06% | 207.179 SH | 1 de Outubro de 2026 | Diário |
| IWM · iShares Trust | 0,06% | 5.937.121 SH | 11 de Setembro de 2026 | Diário |
| DFAS · Dimensional ETF Trust | 0,05% | 770.732 NS | 31 de Julho de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,04% | 1.696.014 SH | 19 de Agosto de 2026 | Diário |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.837.341 SH | 19 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,03% | 624.412 SH | 19 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 99.007 NS | 31 de Julho de 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2.922.024 SH | 19 de Agosto de 2026 | Diário |
| WSML · iShares Trust | 0,01% | 11.812 SH | 11 de Setembro de 2026 | Diário |
| IWV · iShares Trust | 0,00% | 72.998 SH | 11 de Setembro de 2026 | Diário |
| ITOT · iShares Trust | 0,00% | 336.323 SH | 11 de Setembro de 2026 | Diário |
| DFUS · Dimensional ETF Trust | 0,00% | 52.194 NS | 31 de Julho de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 36.571 NS | 31 de Julho de 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 632 NS | 31 de Julho de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 286 NS | 31 de Julho de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 8.070.274 SH | 19 de Agosto de 2026 | Diário |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 196.622 SH | 19 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 19.676 SH | 19 de Agosto de 2026 | Diário |
| ESGV · VANGUARD WORLD FUND | 0,00% | 51.624 SH | 19 de Agosto de 2026 | Diário |
| ISCB · iShares Trust | · | 10.494 SH | 11 de Setembro de 2026 | Diário |
| SMLF · iShares Trust | · | 766.086 SH | 11 de Setembro de 2026 | Diário |
BCRX Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
classificação · 17 analistas
COMPRA
Alvo mediano
$17.00
+108,1%
5 29,4%
Compra forte
10 58,8%
Compra
2 11,8%
Manter
0 0,0%
Venda
0 0,0%
Venda forte
Preço-alvo de 12 meses
11 analistas · 2026-09-28Alvo médio $20.64 +152,6%
← Abaixo de todos os alvos
Preço atual $8.17
Mín$11.00
Média$20.64
Máx$32.00
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | · |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | · |
| VERA | · | -10.9 | · | · | -55.9% | · |
| MLYS | $2.96B | -15.8 | · | · | -32.2% | · |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
Últimas notícias Notícias recentes mencionando esta empresa
RBC Capital eleva PT BioCryst Pharmaceuticals (BCRX) como parte da prévia dos resultados do 1º trimestre de 2026 no setor de biotecnologia.
Yahoo Finance · 5 meses atrás
BioCryst (BCRX) Sobe 7,10% com Rumores de Aquisição
Yahoo Finance · 6 meses, 1 semana atrás
BioCryst Pharmaceuticals, Inc. (BCRX) Um Bom Ação Para Comprar Agora?
Yahoo Finance · 6 meses, 1 semana atrás
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Fonte: SEC 10-Q arquivado Ago 5, 2026